Confo therapeutics enters into research collaboration for gpcr-targeting antibody discovery with abcellera

Ghent, belgium--(business wire)--confo therapeutics, a leader in the discovery of medicines targeting g-protein coupled receptors (gpcrs), today announced that it has entered into a research collaboration with abcellera for the discovery of therapeutic antibody candidates targeting two undisclosed gpcr targets. confo will apply its proprietary confobody® technology to stabilize the selected gpcrs in their disease-relevant conformations, which will then be used as antigens to enable antibody dis.
ABCL Ratings Summary
ABCL Quant Ranking